JMKX-1899 is under clinical development by Jiangxi Jemincare Group and currently in Phase I for Colorectal Cancer. According to GlobalData, Phase I drugs for Colorectal Cancer have a 76% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how JMKX-1899’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

JMKX-1899 overview

JMKX-1899 is under development for the treatment of solid tumor, colorectal cancer and non-small cell lung cancer. The drug candidate acts by targeting the GTP pocket of Kras in the switch II region. It is administered through oral route.

Jiangxi Jemincare Group overview

Jiangxi Jemincare Group (Jemincare) is a manufacturer and supplier of modern Chinese medicine, biological agents and healthcare products. The company offers products for treating kidney, tumor, cardio-cerebrovascular, anti-infection and pediatrics diseases among others. Its products include jinshuibao, xingnaojing, kanglaite, sineng, lixin, huang’s xiangsheng pills, and jiuhua hemorrhoids suppositories. Jemincare has industrial platforms and research and development institutes in Jiangxi, Beijing, Shanghai, Jiangsu and Zhejiang. Jemincare is headquartered in Nanchang, Jiangxi, China.

For a complete picture of JMKX-1899’s drug-specific PTSR and LoA scores, buy the report here.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.